SEC filing summary
Entity and period discrepancy: The supplied filing is for Kintara Therapeutics, Inc. (Nasdaq: KTRA), not Tuhura Biosciences, Inc. It is a Form 10-Q for the three months ended September 30, 2022—Kintara’s fiscal first quarter of fiscal 2023, not calendar 2022 Q1. The filing was signed November 9, 2022. Dollar amounts below are in U.S. dollars.
Business context and reporting period
Kintara is a clinical-stage oncology company with no revenue to date. Its principal program was VAL-083 for glioblastoma (GBM); REM-001 was being developed for cutaneous metastatic breast cancer (CMBC). The financial statements are unaudited.
Financial results and liquidity
| Metric | Quarter ended Sep. 30, 2022 | Prior-year quarter or comparison |
|---|---|---|
| Revenue | None reported | None reported |
| Research and development expense | $3.171 million | $3.793 million; down 16% |
| General and administrative expense | $1.475 million | $2.178 million; down 32% |
| Net loss | $4.596 million | $5.966 million |
| Net loss attributable to common stockholders | $4.960 million | $8.430 million |
| Basic and diluted loss per share | $0.07 | $0.25 |
| Net cash used in operating activities | $6.369 million | $5.073 million |
| Cash and cash equivalents | $7.085 million at Sep. 30 | $11.780 million at Jun. 30 |
| Working capital | $4.640 million at Sep. 30 | $9.268 million at Jun. 30 |
Total assets were $13.210 million and total liabilities were $3.592 million at September 30, 2022. Current liabilities were $3.516 million, including $0.573 million payable to officers and directors. The filing does not disclose conventional borrowings; it reports a $0.076 million milestone-payment liability. No revenue or operating margins are reported, so margins are not meaningful.
Cash used in investing activities was $0.232 million, primarily for equipment. Financing activities provided $1.906 million, mainly net proceeds from common-stock sales under the Lincoln Park purchase agreement. Cash declined by $4.695 million during the quarter. A $4.300 million clinical-trial deposit was recorded as an asset, including $1.700 million paid during the quarter.
Material changes versus the prior comparable period
- Net loss narrowed by $1.370 million; lower R&D and G&A expenses contributed. Management attributed the expense decreases primarily to lower REM-001 study preparation and manufacturing costs, reduced share-based compensation and personnel costs, and lower professional fees.
- Operating cash use increased by $1.296 million, largely reflecting the $1.700 million increase in the clinical-trial deposit and lower accounts payable and accrued liabilities.
- Net loss attributable to common stockholders and loss per share improved substantially, in part because the Series C preferred-stock dividend was $0.362 million versus $2.462 million in the prior-year quarter.
- Common shares outstanding increased from 65.533 million at June 30 to 80.807 million at September 30, including sales under the Lincoln Park facility and the Series C stock dividend.
Outlook, risks, and unusual items
- Going concern: Management said substantial doubt exists about the company’s ability to continue as a going concern within one year from issuance. The company had an accumulated deficit of $141.316 million, no revenue, and estimated cash available for planned operations for less than one year. Additional financing is needed; success is not assured.
- Program prioritization: After quarter-end, Kintara paused REM-001 to conserve cash for VAL-083 and said it expects to save approximately $3.0 million through 2023. No pause-related costs had been recognized as of September 30.
- VAL-083 milestone: Management expected topline results from the GBM AGILE study around the end of calendar 2023, approximately 12 months after the last patient is randomized. The filing reports enrollment at sites in the U.S., Canada, and Europe.
- Financing and dilution: The Lincoln Park agreement provides for purchases of up to $20 million, subject to conditions and limits. The company had received approximately $1.9 million by September 30 and stated that sales then reached the maximum available under Nasdaq ownership limitations. Outstanding warrants, options, and convertible Series C preferred stock create potential further dilution.
- Other risks: Kintara cited uncertainty in capital markets, including COVID-19-related uncertainty, and said it could reduce, delay, or eliminate development programs if it cannot obtain funding. It had until November 28, 2022 to regain compliance with Nasdaq’s minimum bid-price requirement.
- Management reported effective disclosure controls and no material changes in internal control over financial reporting during the quarter. No legal proceedings were reported.
Important facts for investors to verify
- Confirm the intended issuer and period: the supplied filing is Kintara Therapeutics’ September 30, 2022 Form 10-Q, not a Tuhura filing.
- Check subsequent cash, financing, and runway disclosures, including the actual availability of further Lincoln Park purchases and any other funding.
- Verify the status, enrollment, and timing of VAL-083’s GBM AGILE study and any updates to the anticipated topline-results timeline.
- Track the REM-001 pause, realized cost savings, and whether the program resumes or is discontinued.
- Assess dilution from Series C preferred conversion, dividends, warrants, and stock options, and verify Nasdaq listing compliance.